YAZ, Oral Contraceptive Registration in China - Full Text View

Sponsored by:	Bayer
Information provided by:	Bayer
ClinicalTrials.gov Identifier:	NCT00819312

Purpose

The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive YAZ in healthy Chinese women.

Condition	Intervention	Phase
Contraception	Drug: YAZ (SH T00186, BAY86-5300)	Phase III

MedlinePlus related topics: Birth Control

Drug Information available for: Ethinyl estradiol

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
Official Title:	A Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of the Oral Contraceptive YAZ (20μg Ethinylestradiol, 3mg Drospirenone) for 13 Cycles in 670 Healthy Chinese Female Volunteers.

Further study details as provided by Bayer:

Primary Outcome Measures:

The primary efficacy variable is the number of unintended pregnancies as measured by the Pearl Index (PI) during 13 cycles of treatment. [ Time Frame: 13 cycles (1 cycle= 28 days) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Bleeding pattern indices [ Time Frame: 13 cycles ] [ Designated as safety issue: No ]
Cycle control parameters [ Time Frame: 13 cycles ] [ Designated as safety issue: No ]
Adverse events [ Time Frame: Whole study period ] [ Designated as safety issue: Yes ]
Laboratory tests [ Time Frame: Whole study period ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	670
Study Start Date:	December 2008
Estimated Study Completion Date:	January 2011
Estimated Primary Completion Date:	January 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Arm 1: Experimental	Drug: YAZ (SH T00186, BAY86-5300) 20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd

Eligibility

Ages Eligible for Study:	18 Years to 40 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy women between 18 and 45 requesting oral contraception.
Smokers may not exceed 30 years of age.

Exclusion Criteria:

The use of steroidal oral contraceptives , or any drug that could alter oral contraception metabolism will be prohibited during the study.
Pregnancy, lactation (less than 3 menstrual cycles since delivery, abortion or lactation before start of treatment)
Menstrual disorders suspicious of ovarian failure (e.g. oligomenorrhea, amenorrhea, hypomenorrhea
Any disease or condition that may worsen under hormonal treatment
Other contraceptive methods such as sterilization or IUD/IUS
Substantial overweight (BMI > 30 kg/m2).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00819312

Contacts

Contact: Bayer Clinical Trials Contact		clinical-trials-contact@bayerhealthcare.com
Contact: (Phone Menu Options '3' or '4')	(+)1-888-84 22937

Locations

China
	Recruiting
Shanghai, China, 200011
	Recruiting
Shanghai, China, 200127
	Not yet recruiting
Beijing, China, 100034
	Not yet recruiting
Beijing, China, 100044
	Recruiting
Chongqing, China, 400016
	Recruiting
Chongqing, China, 400010
China, Guangdong
	Recruiting
Guangzhou, Guangdong, China, 510630
China, Hubei
	Recruiting
Wuhan, Hubei, China, 430030
China, Jiangsu
	Recruiting
Nanjing, Jiangsu, China, 210009
China, Liaoning
	Recruiting
Shenyang, Liaoning, China, 110003
China, Shandong
	Not yet recruiting
Jinan, Shandong, China, 250012
China, Shanxi
	Recruiting
Xi'an, Shanxi, China, 710032
China, Sichuan
	Recruiting
Chengdu, Sichuan, China, 610041
Hong Kong
	Not yet recruiting
Hong Kong, Hong Kong

Sponsors and Collaborators

Bayer

Investigators

Study Director:

Bayer Study Director

Bayer

More Information

Additional Information:

Click here and search for drug information provided by the FDA This link exits the ClinicalTrials.gov site

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product This link exits the ClinicalTrials.gov site

Click here to find results for studies related to marketed products This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Bayer Schering Pharma AG ( Therapeutic Area Head )
Study ID Numbers:	91619, 311041
Study First Received:	January 5, 2009
Last Updated:	May 4, 2009
ClinicalTrials.gov Identifier:	NCT00819312 History of Changes
Health Authority:	China: State Food and Drug Administration (SFDA)

Keywords provided by Bayer:

Contraceptives,
Oral Hormonal;
Contraceptive Methods;
Contraceptives,
Female

Study placed in the following topic categories:

Estrogens
Contraceptive Agents
Hormone Antagonists
Contraceptives, Oral
Estradiol valerate
Hormones, Hormone Substitutes, and Hormone Antagonists
Contraceptive Agents, Female
Ethinyl Estradiol

Healthy
Estradiol 17 beta-cypionate
Hormones
Estradiol
Estradiol 3-benzoate
Drospirenone
Polyestradiol phosphate

Additional relevant MeSH terms:

Estrogens
Contraceptive Agents
Therapeutic Uses
Physiological Effects of Drugs
Contraceptives, Oral
Hormones, Hormone Substitutes, and Hormone Antagonists

Contraceptive Agents, Female
Ethinyl Estradiol
Reproductive Control Agents
Hormones
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 06, 2009